Viewing Study NCT02569463



Ignite Creation Date: 2024-05-06 @ 7:35 AM
Last Modification Date: 2024-10-26 @ 11:50 AM
Study NCT ID: NCT02569463
Status: UNKNOWN
Last Update Posted: 2015-10-06
First Post: 2015-10-02

Brief Title: Low-dose IL-2 Interleukin-2 Treatment in Macrophage Activation SyndromeMAS
Sponsor: Peking University Peoples Hospital
Organization: Peking University Peoples Hospital

Study Overview

Official Title: Safety and Efficiency Study of Low-dose IL-2 Treatment in Macrophage Activation Syndrome
Status: UNKNOWN
Status Verified Date: 2015-10
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 rhIL-2 for MAS
Detailed Description: Autoimmune-associated macrophage activation syndrome MAS also known as secondary hemophagocytic lymphohistiocytosis HLH is a rapidly progressing life-threatening disease VP16 Etoposide is a well-known standard therapy but is associated with substantial adverse effects especially myelosuppression and infections while steroids and ciclosporin CSA are not always efficient in this disease

The investigators hypothesized that low- dose IL-2 could be a novel therapy in MAS This clinical study will test the efficacy and safety of low dose IL-2 treatment in MAS The investigators perform a single-centre pilot trial with rhIL-2 in MAS The investigators evaluate the effectiveness and safeness of low-dose IL-2 for MAS

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None